Name | [3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate |
---|---|
Synonyms |
Fostemsavir
BMS-663068 {3-[(4-Benzoyl-1-piperazinyl)(oxo)acetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methyl dihydrogen phosphate 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine CS-1059 UNII-97IQ273H4L 1,2-Ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]- [3-[(4-benzoylpiperazin-1-yl)(oxo)acetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate |
Description | Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells. |
---|---|
Related Catalog | |
Target |
HIV-1[1] |
In Vivo | Fostemsavir (BMS-663068) has good antiviral activity in subjects infected with virus shown to be susceptible (IC50, <100 nM) to the agent[1]. |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 904.1±75.0 °C at 760 mmHg |
Molecular Formula | C25H26N7O8P |
Molecular Weight | 583.490 |
Flash Point | 500.6±37.1 °C |
Exact Mass | 583.158020 |
PSA | 192.02000 |
LogP | -2.98 |
Vapour Pressure | 0.0±0.3 mmHg at 25°C |
Index of Refraction | 1.723 |